Pembrolizumab In Central Nervous System Metastases

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Brain Metastases

Interventions

DRUG

Pembrolizumab

RADIATION

MRI

RADIATION

PET/CT

PROCEDURE

Stereotactic Radiosurgery

Trial Locations (2)

Priscilla Brastianos, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER